Citius Pharmaceuticals Inc vs Twist Bioscience Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Twist Bioscience Corp trades at $124 (market cap $7.72B). The key difference: Twist Bioscience Corp is far larger — about 385.8× Citius Pharmaceuticals Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | TWST | |
|---|---|---|
Market Cap | $20.01M | $7.72B |
Sector | Health | Health |
52-Week High | $1.82 | $124.88 |
52-Week Low | $0.48 | $24.16 |
Enterprise Value | $16.23M | $7.65B |
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →